Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Mediolanum Farmaceutici S.p.a.

Maria Alessandra Alisi

Guido Furlotti

Nicola Cazzolla

Giorgina Mangano

Lorenzo Polenzani

Angelo Guglielmotti

Caterina Maugeri

Isabella Coletta

Patrizia Dragone

Barbara Garofalo

Rosella Ombrato

Beatrice Garrone

Francesca Mancini

Stefano Maiorana

Mario Brufani

Pier G Pagella

Vincenzo Russo

Enrico Ferrari

Sperandina Lappa

Maria C Cesta

Gabriele Magaro'

Donata Marchesini

Giuseppe Luna

Gianluca Gostoli

Luigi Filocamo

Gabriele Magaro′

Roberta Costi

Roberto Di Santo

Gabriele Magaro

Luigi Eieocamo

The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E(PGE), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.

3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor

The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general formula (I): 

Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it

The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain. 

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies. 

Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general Formula (I): in which R, R, L, L, X, X, X, X, X, Y, W, m, and n have the meanings stated in the description. 

An (aza)indole derivative substituted in position 5, of formula (I) in which X, Y, Z, G1, G2, G3, R1, W, and R2 have the meanings given in the description, a pharmaceutical composition comprising it, and also intermediate compounds and a preparation process therefor. 

(Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor

Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system. 

Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it

Use of a benzoyl derivative of 3-aminocarbazole to produce a drug for the preventive or therapeutic treatment of a disorder selected form the group comprising inflammatory processes, pain, fever, tumors, Alzheimer's disease and atherosclerosis. Method for the preventive or therapeutic treatment of a disorder selected from the group comprising inflammatory processes, pain, fever, tumors, Alzheimer's disease and atherosclerosis in which a therapeutically effective quantity of a benzoyl derivative of 3-aminocarbazole according to the invention is administered to an individual.

[object Object]

The present invention relates to compounds of formula (II) 

Indazolamides with analgesic activity

2-Alkyl-indazole compound and its pharmaceutically acceptable salts of acid addition, method and intermediates for preparing them, a pharmaceutical composition containing them and use of the latter. The 2-alkyl-indazole compound has the following general formula (I) in which R1, R2, R3, R4, R6, R7, X, Y, W, n, p, and m have the meanings stated in the description. 

2-alkyl-indazole compounds for the treatment of certain cns-related disorders

The present invention relates to a compound of formula (I): in which: R is a linear or branched alkyl group containing between 1 and 3 carbon atoms, Y is CH or N, and p is an integer between 0 and 3 and preferably 0 and 1, and salts thereof, either acid-addition salts with a pharmaceutically acceptable organic or mineral acid, or base-addition salts with a pharmaceutically acceptable organic or mineral base. The invention also relates to a process for preparing the compound of formula (I), and to a pharmaceutical composition comprising it. The invention also relates to the use of an indazole for preparing a pharmaceutical composition that is active in the treatment of neuropathic pain. 

Growing community of inventors

Rome, Italy

Maria Alessandra Alisi